This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Flagship Impella Drive ABIOMED's (ABMD) Q1 Earnings?
by Zacks Equity Research
ABIOMED's (ABMD) flagship Impella receives a slew of regulatory approvals.
Masimo (MASI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Masimo's (MASI) recent developments likely to show on second-quarter results.
LabCorp's (LH) Q2 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.
Align Technology (ALGN) Beats on Q2 Earnings, Margins Fall
by Zacks Equity Research
We are upbeat about Align Technology's (ALGN) continued momentum in Invisalign volumes across all geographies.
Integra Lifesciences' (IART) Earnings Top Estimates in Q2
by Zacks Equity Research
We are upbeat about Integra LifeSciences' (IART) year-over-year revenue growth across key business segments.
Baxter (BAX) Beats on Q2 Earnings & Revenues, Ups EPS View
by Zacks Equity Research
Higher revenues, growth in APAC and raised 2019 EPS outlook benefit Baxter's (BAX) Q2 earnings. However, weak performance at Clinical Nutrition and margin contraction remains a woe.
NextGen (NXGN) Q1 Earnings Lag Estimates, Revenues Down Y/Y
by Zacks Equity Research
NextGen (NXGN) slashes guidance for fiscal 2020 owing to a dismal Q1.
Varian (VAR) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
Varian (VAR) expects revenue growth in the range of 9-10% for fiscal 2019.
Cerner (CERN) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Cerner (CERN) Q2 results benefit from higher revenues, gains in Licensed software, Professional and Managed services units, and gross margin expansion.
What's in the Offing for DexCom's (DXCM) Earnings in Q2?
by Zacks Equity Research
Top-line growth and rising global awareness of the company's real-time CGM are likely to aid DexCom's (DXCM) Q2 earnings.
Thermo Fisher (TMO) Beats on Q2 Earnings, Lifts Guidance
by Zacks Equity Research
Banking on a strong operational performance, Thermo Fisher (TMO) raises its 2019 revenue and earnings guidance.
Neogen's (NEOG) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Neogen's (NEOG) strong international business and solid performance by core Food Safety segment resulted in year-over-year revenue growth.
Boston Scientific (BSX) Q2 Earnings Top on Growth in All Lines
by Zacks Equity Research
Boston Scientific's (BSX) revenue strength across all business lines and geographies raises investors' optimism on the stock.
Medidata (MDSO) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Medidata (MDSO) gains from solid segmental contributions in Q2.
Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View
by Zacks Equity Research
Edwards Lifesciences (EW) Q2 results benefit from higher revenues, strong segmental performance and gross margin expansion.
Can Breast Health Growth Aid Hologic (HOLX) in Q3 Earnings?
by Zacks Equity Research
Hologic (HOLX) is expected to deliver strong third-quarter fiscal 2019 results on robust performance of the breast health segment.
Can Home Health Growth Support Amedisys' (AMED) Q2 Earnings?
by Zacks Equity Research
Within Home Health, Amedisys (AMED) is expected to boost same-store volumes in Q2 via higher admissions and re-certifications.
Can Sequencing Products Drive Illumina's (ILMN) Q2 Earnings?
by Zacks Equity Research
Illumina (ILMN) is expected to deliver a strong second quarter on impressive performance by sequencing portfolio.
Can New Product Menu Aid Zimmer Biomet's (ZBH) Q2 Earnings?
by Zacks Equity Research
With consecutive product approvals, Zimmer Biomet (ZBH) becomes the first company on the global frontier with 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform.
What's in the Offing for PerkinElmer's (PKI) Earnings in Q2?
by Zacks Equity Research
Top-line growth and robust performance at Diagnostics segment are likely to aid PerkinElmer's (PKI) Q2 earnings. However, forex is likely to be a dampener.
Quest Diagnostics (DGX) Q2 Earnings, Revenues Beat Estimates
by Zacks Equity Research
We are upbeat about Quest Diagnostics' (DGX) expanded network access which has helped accelerate volume growth in the second quarter.
DaVita (DVA) Announces Preliminary Q2 Results, View Upbeat
by Zacks Equity Research
Management at DaVita (DVA) expects impressive contribution from calcimimetics in Q2.
What's in Store for Boston Scientific's (BSX) Q2 Earnings?
by Zacks Equity Research
We are upbeat about solid contributions from Boston Scientific's (BSX) Cardiovascular business group, which comprises Interventional Cardiology and Peripheral Interventions.
Can NovoCure's (NVCR) Steady Optune Business Aid Q2 Earnings?
by Zacks Equity Research
NovoCure (NVCR) expects to deliver a strong second quarter on solid performance by Optune business.
Will Core MedSurg Segment Drive Stryker's (SYK) Q2 Earnings?
by Zacks Equity Research
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat second quarter 2019 view are likely to fuel Stryker's (SYK) Q2 earnings. However, forex might be a woe.